International Multicentric Retrospective Study on the Use of EV+P as First-line Therapy in Patients With la/mUC

The ARON-2PLUS Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of Enfortumab vedotin plus Pembrolizumab as first-line therapy in patients with locally advanced/metastatic Urothelial Cancer. Two supplementary optional studies are designed: one is related to CT scans evaluation for 3D reconstruction analysis; the other one is an omic analysis on FFPE tissue.

NCT Number	NCT07420855
Lead Sponsor	Aron Research Foundation Ets
Conditions	Locally Advanced or Metastatic Urothelial Cancer, Urothelial Cancer
Enrollment	361 participants
Start Date	2026-02
Primary Completion	2026-11 (estimated)
Study Completion	2030-12 (estimated)
Updated on ClinicalTrials.gov	2026-02-19